Wide Ranks

KYTX

Kyverna Therapeutics, Inc.

5.43

Top Statistics
Market Cap 234 M Forward PE -1.51 Revenue Growth 0.00 %
Current Ratio 10.50 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.6410 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 321 M Total Cash Per Share 7.45 Total Debt 9 M
Total Debt To Equity 3.02 Current Ratio 10.50 Book Value Per Share 7.01
All Measures
Short Ratio 929.00 % Message Board Id finmb_650816865 Shares Short Prior Month 2 M
Return On Equity -0.5958 City Emeryville Uuid 9393c12b-872b-3012-995e-511005bb16e2
Previous Close 5.06 First Trade Date Epoch Utc 1 B Book Value 7.01
Total Debt 9 M Volume 371762 Price To Book 0.7744
Fifty Two Week Low 3.92 Total Cash Per Share 7.45 Shares Short Previous Month Date 1 B
Target Median Price 28.50 Max Age 86400 Recommendation Mean 1.67
Sand P52 Week Change 0.3133 Target Mean Price 27.33 Net Income To Common -110655000
Short Percent Of Float 0.0698 Implied Shares Outstanding 43 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 344130 Average Volume10days 344130
Total Cash 321 M Next Fiscal Year End 1 B Held Percent Insiders 0.1078
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 5.06 Target Low Price 6.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 5.08 Open 4.88 Free Cashflow -63368752
State CA Dividend Yield 0.00 % Return On Assets -0.3560
Time Zone Short Name EST Trailing Eps -2.96 Day Low 4.88
Address1 5980 Horton Street Shares Outstanding 43 M Price Hint 2
Target High Price 48.00 Website https://kyvernatx.com 52 Week Change -0.8196
Average Volume 336464 Forward Eps -3.93 Recommendation Key buy
Compensation As Of Epoch Date 1 B Quick Ratio 1037.90 % Is_sp_500 False
Regular Market Day High 5.50 Profit Margins 0.00 % Debt To Equity 3.02
Fifty Two Week High 30.60 Day High 5.50 Shares Short 2 M
Regular Market Open 4.88 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.0536 Operating Cashflow -95752000
Currency USD Time Zone Full Name America/New_York Market Cap 234 M
Is_nasdaq_100 False Zip 94608 Quote Type EQUITY
Industry Biotechnology Long Name Kyverna Therapeutics, Inc. Regular Market Day Low 4.88
Held Percent Institutions 0.7616 Current Price 5.43 Address2 Suite 550
Enterprise To Ebitda 0.6410 Financial Currency USD Current Ratio 10.50
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 22 M Two Hundred Day Average 12.61 Enterprise Value -78052360
Forward PE -1.51 Regular Market Volume 371762 Ebitda -121746000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases.

Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.

The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases.

In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis.

Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases.

The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.

Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.